What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

November 27, 2022

Chad Pettit, the executive director of marketing and global biosimilars commercial lead at Amgen, discusses the most recent version of Amgen's Biosimilar Trends Report and what the report says about the current biosimilar market and how it could develop in the years to come.

VOLTAIRE-X Findings in Patients With Chronic Plaque Psoriasis Supported Interchangeability

November 26, 2022

The Top 5 Biosimilar Articles for the Week of November 21

November 25, 2022

Alvotech Snags Australian Approval for Adalimumab Biosimilar

November 24, 2022

Rezvoglar Becomes Second Interchangeable Insulin Biosimilar

November 23, 2022

AAO Posters Investigate Ranibizumab Biosimilar Impact on Patient Outcomes

November 2nd 2022

By Skylar Jeremias

Article

Two studies presented at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, demonstrated the impact that a ranibizumab biosimilar (SB11; Byooviz) can have on patient outcomes.

AAM Report: Biosimilars, Generics Generated Billions of Dollars in Savings in 2021

November 1st 2022

By Skylar Jeremias

Article

Biosimilar and generic drugs accumulated $373 billion in savings in 2021, $7 billion of which can be attributed to biosimilars alone, according to a report from the Association for Accessible Medicines (AAM).

Biosimilars Policy Roundup: October 2022

October 31st 2022

By Skylar Jeremias

Article

October ushered in a number of policy updates, including the implementation of a biosimilars switching policy, the European Union declaration of biosimilars as interchangeable, and the reauthorization of the Biosimilars User Fee Act.

Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy

October 30th 2022

By Skylar Jeremias

Video

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, offers advice to health systems on how they can incorporate some of Emory Healthcare's strategies to promote biosimilar uptake.

Overview of Trastuzumab Biosimilars in HER2-Positive Breast Cancer

October 29th 2022

By Deana Ferreri, PhD

Article

Authors of a systematic review summarized the results of 21 published studies on the efficacy, safety, and cost-benefit ratio of trastuzumab biosimilars in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

The Top 5 Biosimilar Articles for the Week of October 24

October 28th 2022

By Skylar Jeremias

Article

Here are the top 5 biosimilar articles for the week of October 24, 2022.

Similis Bio Makes Its First Licensing Deal for 4 Biosimilars in Latin America

October 27th 2022

By Skylar Jeremias

Article

Similis Bio signed a licensing and codevelopment agreement with Blau Farmacêutica, allowing the latter to have exclusive development and marketing rights to 4 biosimilar assets in Latin America.

Dr Ivo Abraham Column: Biosimilars and the Commoditization of Treatments

October 26th 2022

By Ivo Abraham, PhD

Article

Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores whether biosimilars should be considered a commodity and if the commodification of medications is sustainable as the market continues to expand.

It’ll Take a Village: Collaborative Efforts Needed to Increase Ophthalmology Biosimilar Uptake

October 25th 2022

By Skylar Jeremias

Article

Speakers during a LinkedIn Live panel discussion expressed a dire need for all stakeholders to work together to increase education efforts, provide clarity on safety and interchangeability, and encourage adoption of biosimilars in ophthalmology.

Genentech, Roche Recall Ophthalmology Biobetter Susvimo

October 24th 2022

By Skylar Jeremias

Article

Genentech and Roche have voluntarily recalled their ophthalmology biobetter, Susvimo, an ocular implant for ranibizumab injection, in the United States for a possible leakage issue.